^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GD2, PSMA and CD276 CAR-T

    i
    Other names: GD2, PSMA and CD276 CAR-T, 4SCAR-T Therapy Targeting GD2, PSMA and CD276
    Associations

    News

    Trials
    Company:
    SZGIMI
    Drug class:
    B7-H3-targeted CAR-T immunotherapy, PSMA-targeted CAR-T immunotherapy, GD2-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    7d
    4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2030 | Trial primary completion date: Nov 2020 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    4SCAR-T • GD2, PSMA and CD276 CAR-T